Please Wait.....
Report
Vertex Pharmaceuticals Incorporated (VRTX:NASD) Strategic SWOT Analysis and Financial Insights - A 360? Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI?s, and Recent Trends
Company Report I 2025-02-27 I 118 Pages I Quaintel Research
Report Summary
Vertex Pharmaceuticals Incorporated (VRTX:NASD) Strategic SWOT Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPIs, and Recent Trends Report is a comprehensive and easily accessible overview of Vertex Pharmaceuticals Incorporated's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about Vertex Pharmaceuticals Incorporated, including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses Vertex Pharmaceuticals Incorporated's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Vertex Pharmaceuticals Incorporated's overall strategic standing and supports informed decision-making and strategic planning.
The report also covers Vertex Pharmaceuticals Incorporated's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Vertex Pharmaceuticals Incorporated's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.
Finally, the report includes recent news and deal activities undertaken by Vertex Pharmaceuticals Incorporated, enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
Vertex Pharmaceuticals Incorporated operates as a biotechnology company that develops and commercializes therapies for the treatment of cystic fibrosis. Vertex Pharmaceuticals operates in two key business segments - (1) Developing and commercializing therapies for cystic fibrosis, its core area of focus (2) Research and development programs for treatments of other serious diseases like pain, cancer, sickle cell disease etc. Vertex Pharmaceuticals offers products and services focused on cystic fibrosis treatments. It has developed and markets medicines like TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO to treat cystic fibrosis in patients based on their age and genetic mutations. The company also has a robust pipeline of investigational medicines like VX-522, VX-548, Exa-cel and VX-864 that are being evaluated in clinical trials for various diseases. Founded in 1989, the company is headquartered in Boston, Massachusetts, United States.
Vertex Pharmaceuticals Incorporated in the News:-
- 31-Jan-2025 - Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
- 30-Jan-2025 - Vertex Announces FDA Approval of JOURNAVX (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
- 20-Dec-2024 - Vertex Announces US FDA Approval of ALYFTREK, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
- 25-Oct-2024 - Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
- 18-Oct-2024 - Vertex to Present Phase 3 Data Highlighting Suzetrigines Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting
Scope
Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
Comprehensive Understanding of the Vertex Pharmaceuticals Incorporated's internal and external factors through SWOT analysis, Financial Analysis, and Competitors Benchmarking.
Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company Vertex Pharmaceuticals Incorporated:
Vertex Pharmaceuticals Incorporated PESTLE Analysis
Vertex Pharmaceuticals Incorporated Porter's Five Forces Analysis
Vertex Pharmaceuticals Incorporated VRIO Analysis
Vertex Pharmaceuticals Incorporated BCG Analysis
Vertex Pharmaceuticals Incorporated Segmentation, Targeting and Positioning (STP) Analysis
Vertex Pharmaceuticals Incorporated Ansoff Matrix Analysis
Table of Contents
COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 6
Charts 7
Vertex Pharmaceuticals Incorporated - Key Company Facts 8
Vertex Pharmaceuticals Incorporated - Company Description 9
Vertex Pharmaceuticals Incorporated - Top Executives 10
Vertex Pharmaceuticals Incorporated- Top Executives Biographies 11
Vertex Pharmaceuticals Incorporated- Head Office & Locations 14
Head Office - Country 14
Key Subsidiaries 15
Vertex Pharmaceuticals Incorporated - Products and Services 16
Products 16
Services 17
Vertex Pharmaceuticals Incorporated - Historic Events 18
Vertex Pharmaceuticals Incorporated - Corporate Strategy 20
Vertex Pharmaceuticals Incorporated - Business Description 27
CF 29
Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia 29
Vertex Pharmaceuticals Incorporated - ESG Spotlight 31
Environment 31
Social 32
Corporate Governance 33
Vertex Pharmaceuticals Incorporated - SWOT Analysis 34
Overview 34
Strengths 36
Weaknesses 38
Opportunities 39
Threats 41
Vertex Pharmaceuticals Incorporated - Financial Deep Dive 43
Share Price Trend - Feb-2024 to Feb-2025 (Average Share Closing Price) 43
Profit and Loss Statement 45
Summary of Profit and Loss Statement 45
Balance Sheet 47
Summary of Balance Sheet 47
Cash Flow Statement 49
Summary of Cash Flow Statement 49
Key Financial Ratio Analysis 51
Vertex Pharmaceuticals Incorporated - Ratio Charts 52
Activity Ratio Charts 52
Growth Ratios Charts 53
Leverage Ratio Charts 54
Liquidity Ratio Charts 55
Profitability Ratio Charts 56
Competing Players 57
Snapshot of Competing Players 58
AbbVie Inc 58
Key Company Facts 58
Company Description 58
Snapshot of Competing Players 59
Bristol-Myers Squibb Company 59
Key Company Facts 59
Company Description 59
Snapshot of Competing Players 60
GSK plc 60
Key Company Facts 60
Company Description 60
Snapshot of Competing Players 61
Arcturus Therapeutics Holdings Inc 61
Key Company Facts 61
Company Description 61
Snapshot of Competing Players 62
Krystal Biotech Inc 62
Key Company Facts 62
Company Description 62
Vertex Pharmaceuticals Incorporated - In the News 63
31-Jan-2025 -Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease in England 63
30-Jan-2025 -Vertex Announces FDA Approval of JOURNAVX (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain 64
20-Dec-2024 -Vertex Announces US FDA Approval of ALYFTREK, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis 64
25-Oct-2024 -Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress 66
18-Oct-2024 -Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting 69
26-Sep-2024 -Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA at the North American Cystic Fibrosis Conference 71
15-May-2024 -Jennifer Schneider Elected to Vertex Board of Directors 74
26-Apr-2024 -Vertex Announces European Commission Approval for KALYDECO to Treat Infants With Cystic Fibrosis Ages 1 Month and Older 74
18-Apr-2024 -Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain 77
01-Apr-2024 -Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease 79
21-Mar-2024 -Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) 81
13-Feb-2024 -European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia 83
05-Feb-2024 -Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis 85
30-Jan-2024 -Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain 88
16-Jan-2024 -Vertex Announces US FDA Approval of CASGEVY (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia 90
09-Jan-2024 -Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia 93
15-Dec-2023 -Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia 96
Vertex Pharmaceuticals Incorporated - Key Deals 100
10-Jan-2025 - Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore 100
23-Apr-2024 - Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex's Cell Therapies for Type 1 Diabetes 101
10-Apr-2024 - Vertex Enters Into Agreement to Acquire Alpine Immune Sciences 101
27-Mar-2023 - Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes 105
08-Dec-2022 - Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) 105
04-Nov-2022 - Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD) 108
20-Jul-2022 - Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease 110
Appendix 111
Definitions 111
SWOT Analysis 111
PESTLE Analysis 111
Value Chain Analysis 111
ESG Spotlight 111
Financial Deep Dive 111
Financial Ratios - 112
Activity Ratios 112
Growth Ratios 113
Leverage Ratios 114
Liquidity Ratios 115
Market Ratios 116
Profitability Ratios 116
Research Methodology 117
Disclaimer 118
Contact Us 118
Tables
Table 1: Vertex Pharmaceuticals Incorporated - Company Facts
Table 2: Vertex Pharmaceuticals Incorporated - Digital Presence
Table 3: Vertex Pharmaceuticals Incorporated - Top Executives
Table 4: Vertex Pharmaceuticals Incorporated - Top Executives Biographies
Table 5: Vertex Pharmaceuticals Incorporated - Subsidiaries
Table 6: Vertex Pharmaceuticals Incorporated - Products
Table 7: Vertex Pharmaceuticals Incorporated - Services
Table 8: Vertex Pharmaceuticals Incorporated - Historic Events
Table 9: Vertex Pharmaceuticals Incorporated - Share Price Trend - Feb-2024 to Feb-2025
Table 10: Vertex Pharmaceuticals Incorporated - Ratio Analysis - 2020-2023
Table 11: Vertex Pharmaceuticals Incorporated - Competing Players
Table 12: Competing Players - AbbVie Inc - Key Company Facts
Table 13: Competing Players - Bristol-Myers Squibb Company - Key Company Facts
Table 14: Competing Players - GSK plc - Key Company Facts
Table 15: Competing Players - Arcturus Therapeutics Holdings Inc - Key Company Facts
Table 16: Competing Players - Krystal Biotech Inc - Key Company Facts
Charts
Figure 1: Vertex Pharmaceuticals Incorporated- SWOT Analysis
Figure 2: Vertex Pharmaceuticals Incorporated - Average Share Price Trend - Feb-2024 to Feb-2025
Figure 3: Vertex Pharmaceuticals Incorporated - Profit and Loss Statement - 2021-2024
Figure 4: Vertex Pharmaceuticals Incorporated - Balance Sheet - 2021-2024
Figure 5: Vertex Pharmaceuticals Incorporated - Cash Flow Statement 2021-2024
Figure 6: Vertex Pharmaceuticals Incorporated - Activity Ratio Charts
Figure 7: Vertex Pharmaceuticals Incorporated - Growth Ratio Charts (Value %)
Figure 8: Vertex Pharmaceuticals Incorporated - Leverage Ratio Charts
Figure 9: Vertex Pharmaceuticals Incorporated - Liquidity Ratio Charts
Figure 10: Vertex Pharmaceuticals Incorporated - Profitability Ratio Charts (Value %)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security